We are pleased to present two recent Journal of Hematology & Oncology thematic series:
Collections open for submissions
- First-in-human clinical trials for cancer and blood disorders
- How we treat
- New developments in delivery technology, materials, and molecular engineering for drug discovery
Deepak Sethi / Getty Images / iStock.
First-in-human clinical trials for cancer and blood disorders
This series calls for clinical studies on novel agents for cancers and blood disorders. Summaries and reviews on first-in-human or first-in-class studies are also welcome.
The deadline for submissions is 31 October 2021.
xixinxing / Fotolia.
How we treat
This series will focus on guidelines, consensus, and multidisciplinary approaches on cancers and blood disorders. All submissions to this series should be either invited or pre-approved. Prospective authors should contact the Journal Development Manager for pre-approval at aoife.buckley@springernature.com. The deadline for submissions is 31 October 2021.
weyo / stock.adobe.com
New developments in delivery technology, materials, and molecular engineering for drug discovery
This series covers new technology, materials, and models for drug discovery. Development and applications of organoids, 3D cultures, PDX modes, nano-molecules, AI technology, and single-cell maps for drug discovery will be the focus. The deadline for submissions is 31 October 2021.
Thematic series
Aims and scope
Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology. Read more.
Articles
-
-
Targeting neddylation E2s: a novel therapeutic strategy in cancer
-
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins
-
Novel therapies emerging in oncology to target the TGF-β pathway
-
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
-
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
-
The effects of β-glucan on human immune and cancer cells
-
The diagnosis and management of NK/T-cell lymphomas
-
Mechanism of action of lenalidomide in hematological malignancies
-
Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers
Editor's quote
"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."
Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology
Experimental Hematology & Oncology
Submit your research to our companion journal, Experimental Hematology & Oncology
-
Official journal of
-
Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
-
- Editorial Board
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Speed
36 days to first decision for reviewed manuscripts only
14 days to first decision for all manuscripts
69 days from submission to acceptance
20 days from acceptance to publication
Citation Impact
11.059 - 2-year Impact Factor
8.474 - 5-year Impact Factor
1.923 - Source Normalized Impact per Paper (SNIP)
3.231 - SCImago Journal Rank (SJR)
Usage
1,463,020 Downloads
1153 Altmetric Mentions
On the blog
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).
